Free Trial

Beyond Air Q2 2024 Earnings Report

Beyond Air logo
$0.40 -0.01 (-3.12%)
(As of 12/20/2024 05:40 PM ET)

Beyond Air EPS Results

Actual EPS
-$0.51
Consensus EPS
-$0.47
Beat/Miss
Missed by -$0.04
One Year Ago EPS
N/A

Beyond Air Revenue Results

Actual Revenue
$0.24 million
Expected Revenue
$0.50 million
Beat/Miss
Missed by -$260.00 thousand
YoY Revenue Growth
N/A

Beyond Air Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

This Indicator called BOTH NVDA rallies (Ad)

Rarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is…

Click this link here. 
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Beyond Air? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Beyond Air and other key companies, straight to your email.

About Beyond Air

Beyond Air (NASDAQ:XAIR) operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

View Beyond Air Profile

More Earnings Resources from MarketBeat

Upcoming Earnings